SCHEMBL12596186

SCHEMBL12596186

c1ccc(-c2ccc(N(c3ccc(-n4c5ccccc5c5ccccc54)cc3)c3c4ccccc4c(N(c4ccc(-c5ccccc5)cc4)c4ccc(-n5c6ccccc6c6ccccc65)cc4)c4ccccc34)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
KDM4E B2RXH2 2/20 0.53
ATM Q13315 1/20 0.53
HDAC4 P56524 1/20 0.43
KMT2A Q03164 3/20 0.38
IL1R1 P14778 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 1/20 0.37
PTPN1 P18031 2/20 0.35
MAPK8 P45983 1/20 0.35
HTR7 P34969 1/20 0.35
TSPO P30536 1/20 0.35
HSP90AA1 P07900 1/20 0.33
AVPR1A P37288 1/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
AKR1C4 P17516 1/20 0.32
AKR1C3 P42330 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12596197 0.97 L3MBTL1 (0.53) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL12596161 0.94 KDM4E (0.47) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL12596165 0.93 L3MBTL1 (0.46) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL12596100 0.93 L3MBTL1 (0.46) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL12367630 0.92 L3MBTL1 (0.59) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL20813037 0.92 L3MBTL1 (0.59) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL10029895 0.92 L3MBTL1 (0.59) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL20732492 0.92 L3MBTL1 (0.59) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL21971478 0.92 L3MBTL1 (0.59) L3MBTL1KDM4EATMHDAC4KMT2A
SCHEMBL15964455 0.92 L3MBTL1 (0.59) L3MBTL1KDM4EATMHDAC4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066629-B1 ANTHRACENE DERIVATIVE, AND LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LAB (JP) 2017-05-17 EP disclosed
US-8546792-B2 Anthracene derivative, and light emitting element, light emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-10-01 US disclosed
US-8546792-B2 Anthracene derivative, and light emitting element, light emitting device, and electronic device using the anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-10-01 US disclosed
US-20110121275-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-05-26 US disclosed
US-7880019-B2 9-[N-phenyl-N-(9-phenylcarbazol-3-yl)amino]-10-phenylanthracene; high luminous efficiency; long lifetime SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-02-01 US disclosed
US-7880019-B2 9-[N-phenyl-N-(9-phenylcarbazol-3-yl)amino]-10-phenylanthracene; high luminous efficiency; long lifetime SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-02-01 US disclosed
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-04-10 US disclosed
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-04-10 US disclosed
WO-2008038607-A1 ANTHRACENE DERIVATIVE, AND LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE ANTHRACENE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080086012-A1 Anthracene Derivative, And Light Emitting Element, Light Emitting Device, And Electronic Device Using the Anthracene Derivative GLB1, CYP1A1, XPOT L3MBTL1 716/4885KDM4E 3720/4885ATM 1176/4885
US-20110121275-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, and Electronic Device Using the Anthracene Derivative GLB1, CYP1A1, XPOT L3MBTL1 716/4885KDM4E 3720/4885ATM 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.